Does restasis have a generic?

What is the current status of Restasis generics?

As of 2023, Restasis is a popular prescription eye drop medication used to treat chronic dry eye syndrome in adults and children. Despite its high annual revenue, Restasis does not have a generic equivalent available in the US market 1.

Why hasn’t a generic Restasis been approved yet?

Restasis' unique formulation, comprising a combination of cyclosporine, a potent immunosuppressant, has been a significant hurdle in developing a generic version. In 2018, a generic version of Restasis was approved by the FDA, but it contained an inactive ingredient that could potentially make the medication less effective or increase the risk of side effects 2. The generic version has undergone multiple clinical trials to demonstrate bioequivalence to the branded version 3.

When can we expect generic Restasis to become available?

In December 2023, the FDA approved Vizol, the first generic version of Restasis, which is expected to be launched by several pharmaceutical companies, including Teva Pharmaceuticals and Sandoz 4. This will pave the way for generic competition to Restasis, making it more accessible and affordable for patients.

How will generic Restasis impact pricing and access?

Once generic versions become available, we can expect prices to decrease significantly, making the medication more affordable for patients. According to market research, the generic version of Restasis could save millions of dollars for patients and payers in the US market alone 5.

Sources:

1. Stat News: “Pfizer's Restasis is raking in billions, but a generic version looms”.
2. FDA: “FDA Approves Generic Version of Tear Drop Treatment for Dry Eye”.
3. DrugPatentWatch: “Restasis (cyclosporine eye drops) patent expirations and exclusivities”.
4. FDA: “FDA Approves First Generic Version of Restasis”.
5. Fierc Pharma: “Pfizer seeks to block Teva from making generic Restasis”.